secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2022-10-25T23:59:59+00:00
Accession:  0001193125-22-267965
Event type: m_and_a
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology increases ownership in MICA subsidiary to 92% for $30.7M
--------------------------------------------------------------------------

- Purchased 14.97M shares from Avalon Ventures and Bregua Corp at $2.05/share, totaling $30.7M.
- Ownership in MICA (holder of CLN-619 rights) increased from 54% to 92%.
- MICA holds worldwide rights to CLN-619, a monoclonal antibody targeting MICA/MICB pathway.
- Phase I trial of CLN-619 (monotherapy + combo with checkpoint inhibitor) on track for initial data in mid-2023.
- Myeloma Investment Fund (MMRF) retained its existing ownership stake in MICA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522267965/0001193125-22-267965-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312522267965/d390289d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-267965

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer